U.S. flag

An official website of the United States government

NM_000051.4(ATM):c.4802G>A (p.Ser1601Asn) AND not specified

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Sep 4, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000779764.2

Allele description [Variation Report for NM_000051.4(ATM):c.4802G>A (p.Ser1601Asn)]

NM_000051.4(ATM):c.4802G>A (p.Ser1601Asn)

Gene:
ATM:ATM serine/threonine kinase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
11q22.3
Genomic location:
Preferred name:
NM_000051.4(ATM):c.4802G>A (p.Ser1601Asn)
HGVS:
  • NC_000011.10:g.108294952G>A
  • NG_009830.1:g.77121G>A
  • NM_000051.4:c.4802G>AMANE SELECT
  • NM_001351834.2:c.4802G>A
  • NP_000042.3:p.Ser1601Asn
  • NP_000042.3:p.Ser1601Asn
  • NP_001338763.1:p.Ser1601Asn
  • LRG_135t1:c.4802G>A
  • LRG_135:g.77121G>A
  • LRG_135p1:p.Ser1601Asn
  • NC_000011.9:g.108165679G>A
  • NM_000051.3:c.4802G>A
  • p.S1601N
Protein change:
S1601N
Links:
dbSNP: rs587782506
NCBI 1000 Genomes Browser:
rs587782506
Molecular consequence:
  • NM_000051.4:c.4802G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001351834.2:c.4802G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000916546Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Uncertain significance
(Sep 4, 2022)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Global analysis of ATM polymorphism reveals significant functional constraint.

Thorstenson YR, Shen P, Tusher VG, Wayne TL, Davis RW, Chu G, Oefner PJ.

Am J Hum Genet. 2001 Aug;69(2):396-412. Epub 2001 Jul 3.

PubMed [citation]
PMID:
11443540
PMCID:
PMC1235311

ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy.

Paglia LL, Laugé A, Weber J, Champ J, Cavaciuti E, Russo A, Viovy JL, Stoppa-Lyonnet D.

Breast Cancer Res Treat. 2010 Jan;119(2):443-52. doi: 10.1007/s10549-009-0396-z. Epub 2009 Apr 29.

PubMed [citation]
PMID:
19404735
See all PubMed Citations (3)

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV000916546.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

Variant summary: ATM c.4802G>A (p.Ser1601Asn) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 251834 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.4802G>A has been reported in the literature in individuals with a variety of ATM-related cancers such as BRCA1/2-negative breast cancer, 11q deletion Chronic Lymphocytic Leukemia (CLL) (example, Pagila_2010, Skowronska_2011). These report(s) do not provide unequivocal conclusions about association of the variant with Ataxia-Telangiectasia/Breast/ATM-related cancers. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Seven clinical diagnostic laboratories and the Spanish ATM Cancer Susceptibility Variant Interpretation Working Group have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple submitters reported the variant with conflicting assessments (VUS, n=4; likely benign, n=4). Based on the evidence outlined above, the variant was classified as uncertain significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 3, 2024